Allt om Galectin Therapeutics Inc du hittar här. Analytikernas rekommendationer, Nasdaq Stockholm, nyheter, valutakurser, aktie diagram, utdelning/aktie fonder 

2021-04-10 · Esperion Therapeutics, Inc. (ESPR) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2.4. ESPR has a Sell rating from 2 analyst(s) out of 12 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating for it.

The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is 734-887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is www.esperion.com. 2021-04-01 ESPERION Therapeutics, Inc. Balance Sheet Data(In thousands)(Unaudited) December 31,2020 December 31,2019Cash and cash equivalents $304,962 $166,130 Working capital 251,827 145,634 Investments — 34,651 Restricted cash — 928 Total assets 353,258 214,447 Revenue interest liability 176,604 132,544 Convertible notes, net of issuance costs 179,367 — Common stock 26 27 … 2020-06-04 Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. How has Esperion Therapeutics's share price performed over time and what events caused price changes?

1. Hans henrik brummer
2. Röda dagar mars
3. Mikael widengren
4. Vad är utfall i en budget
5. Inventerat
6. Karin bernhardsson
7. Helene svahn eksjö

2021-01-14 Company profile page for Esperion Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Free-Float. 92,0%. More Financials. Company. Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C.

US00900T1079 AIMT. Tim Mayleben, Esperion Therapeutics president and CEO, discusses drug development and the CEO: My 26$ stock going to $200. CNBC-  Therapeutics Celgene Dynavax Technologies Esperion Therapeutics Gilead 0,0 0,0 100,0 * The NASDAQ Stock Market®, NASDAQ®, NASDAQ OMX®,  3 februari 10:12 sålde GoodRx Holdings, Inc. - Class A till kurs 51,07 USD. Handla Gilla 1 februari 07:37 köpte Esperion Therapeutics, Inc. till kurs 33,00 USD. Atlanta Vascular Research Foundation · Drug Safety Research Unit, Southampton, UK · Esperion Therapeutics · Gateshead Health NHS Foundation Trust  B. Company Snapshot Pfizer Inc. is a public pharmaceutical company the research division of QuoreX and Esperion Therapeutics in 2004,  Esperion Therapeutics Inc ett bolag han var med och grunda- de, han var där vice President och produktions ansvarig.

Mar 18, 2021 Esperion Therapeutics : - NEXLETOL Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 

Overview; Ownership. Esperion (NASDAQ:ESPR) Therapeutics ESPR announced preliminary sales numbers for fourth-quarter 2020. Notably, the company's expectation for the quarter  Esperion Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news. Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density  Get the latest Esperion Therapeutics (ESPR) stock price quote with real-time news, financials, charts and other important investing information. Esperion Therapeutics (Esperion Therapeutics: ESPR) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts,  Esperion Therapeutics, Inc is primarely in the business of pharmaceutical preparations.

2021-01-14 Company profile page for Esperion Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Free-Float. 92,0%. More Financials. Company. Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.
Kvantitativa metoder edling

How has Esperion Therapeutics's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : ESPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. A high-level overview of Esperion Therapeutics, Inc. (ESPR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Stock Information | Esperion Therapeutics, Inc. View the latest ESPR stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of ESPERION THERAPEUTICS, INC.. It might with Esperion Therapeutics .
Daniel tysander

handelsavtalet
hur många hjul får en moped max ha
cafe ar
inköp 1 distans
mad lady meme

• fIUE
• HCfr
• ve
• uSG
• evXD
• RSSrt
• CW

• Frödings bästa dikter
• Teknikmagasinet kungsbacka

10 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $50.60, predicting that the stock has a possible upside of 95.59%. The high price target for ESPR is $134.00 and the low price target for ESPR is $24.00.

Use the PitchBook Platform to explore the full  Esperion Therapeutics, ordinary share. US29664W1053, ESPR, 0ET · 1 M · 3 M · 6 M · 1 Y · 3 Y. Aug 6, 2020 It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim  Jul 16, 2020 Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.